Thompson M, Westwick J, Woodward B
School of Pharmacy and Pharmacology, University of Bath, Avon, England.
J Cardiovasc Pharmacol. 1995 Jan;25(1):156-62. doi: 10.1097/00005344-199501000-00024.
Coronary constrictor actions of endothelin-1 (ET-1) are enhanced after myocardial ischemia/reperfusion (I/R), possibly owing to enhanced ETA-receptor-mediated constriction and/or loss of the opposing ETB-receptor-mediated vasodilatation. We examined the actions of ET-1, ET-2, and ET-3 and the selective ETB-receptor agonist sarafotoxin 6c (Sx6c) after I/R in perfused rat heart. To examine the effects of a loss of ETB-receptor-mediated vasodilatation on coronary constrictor responses to ET-1, we used repeated doses of Sx6c to desensitize ETB receptors. After I/R, the coronary constrictor effects of all three ETs were enhanced, whereas their initial vasodilator effects were inhibited. The pure coronary dilator effect of Sx6c observed in control hearts was also inhibited after I/R. After desensitization of ETB receptors, the coronary constrictor action of ET-1 was enhanced by an amount equivalent to the vasodilatation that had been lost. This enhancement of constriction was not as marked as that noted after I/R, suggesting that the enhanced coronary constrictor action of ET-1 after I/R is not simply due to loss of opposing ETB-receptor-mediated vasodilatation and that other mechanisms are involved. The most likely explanation is upregulation of functional ETA receptors after I/R because ETB-receptor stimulation did not cause coronary constriction in this preparation. The vasoconstrictor enhancement therefore is likely to be the combined effect of receptor upregulation and vasodilator loss.
心肌缺血/再灌注(I/R)后,内皮素-1(ET-1)的冠状动脉收缩作用增强,这可能是由于ETA受体介导的收缩增强和/或ETB受体介导的血管舒张作用丧失所致。我们研究了I/R后ET-1、ET-2和ET-3以及选择性ETB受体激动剂沙拉毒素6c(Sx6c)在灌注大鼠心脏中的作用。为了研究ETB受体介导的血管舒张丧失对冠状动脉对ET-1收缩反应的影响,我们使用重复剂量的Sx6c使ETB受体脱敏。I/R后,所有三种ET的冠状动脉收缩作用均增强,而它们最初的血管舒张作用受到抑制。I/R后,对照心脏中观察到的Sx6c的单纯冠状动脉舒张作用也受到抑制。ETB受体脱敏后,ET-1的冠状动脉收缩作用增强的幅度相当于丧失的血管舒张作用。这种收缩增强不如I/R后明显,这表明I/R后ET-1冠状动脉收缩作用增强并非仅仅由于ETB受体介导的血管舒张作用丧失,还涉及其他机制。最可能的解释是I/R后功能性ETA受体上调,因为在本实验中刺激ETB受体并未引起冠状动脉收缩。因此,血管收缩增强可能是受体上调和血管舒张丧失的综合作用。